In contrast to this, consistent reports of hypokalaemia in patients with severe COVID-19 (61, 62) suggest an increase in aldosterone, via elevations in Ang II, resulting in an increase in ACE, which acts to metabolize bradykinin (63). This evidence concerns the gene ACE and COVID-19.